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Abstract
In the chronic state of inﬂammatory diseases, cellular signaling networks aimed at combating invading
pathogens are often constitutively active and transmit their signals even in the absence of inﬂammatory
agents. Thus, many anti-inﬂammatory drugs interfere with these dys- and hyperactivated cellular signaling
networks or transcription factors. As many signaling molecules fulﬁll important and essential functions in
normal cell physiology, their systemic and long-term inhibition may lead to severe side eﬀects including an
impaired immune response. To circumvent these pitfalls, two possibilities are proposed and discussed here:
(I) Since many inﬂammatory diseases such as rheumatoid arthritis or inﬂammatory bowel disease are
restricted to certain cell types or tissues, a new generation of anti-inﬂammatory drugs would target enzymes
that are only operational in these aﬀected tissues. (II) As some signaling pathways aﬀect solely a small
subset of inﬂammatory target genes, their inhibition bears the potential of limiting potential side eﬀects.
Abbreviations: COX-2 – cyclooxygenase-2; TNFa – tumor necrosis factor a; IL – interleukin; LPS –
lipopolysaccharide; MAPKs – mitogen-activated protein kinases; ERK – extracellular-signal-regulated
kinase; JNK – c-Jun N-terminal kinase; MAPKKs – MAPK kinases; MAPKKKs – MAPK kinase kinases;
MMP – matrix metalloproteinase; TAB1 – transforming growth factor-b-activated protein kinase 1
(TAK1)-binding protein 1; NSAIDs – non-steroidal anti-inﬂammatory drugs; TCR – T cell receptor;
C/EBP – CCAAA/enhancer-binding protein; LTb – lymphotoxin b.
Inﬂammation
Inﬂammation can be caused by a variety of stim-
uli including physical damage, UV irradiation,
immune reactions and microbial invasion. The
classical key features of inﬂammation are redness,
warmth, swelling and pain. Besides systemic features
such as fever and the acute phase response, inﬂam-
mation is a primarily local event. The inﬂammatory
process attracts leukocytes from the intravascular
compartment to the site of damage, which is medi-
ated by cytokines, chemokines, cell surface proteins
and further mechanisms (Johnston and Butcher,
2002; Marra, 2002). In addition, the inﬂammatory
process leads to an induced expression and
enzymatic activity of enzymes such as cyclooxygen-
ase-2 (COX-2) and NO synthase which produce
inﬂammatory mediators such as eicosanoids and
NO. These mediators serve to augment the local
blood ﬂow. Invading microorganisms are engulfed
by phagocytic cells including neutrophils and
macrophages in order to maintain the infection in
a restricted space. During phagocytosis, an oxi-
dative burst helps to destroy the invading patho-
gens (Winrow et al., 1993; Marra, 2002).
Phagocytic cells also remove tissue debris and
dead cells. Damage is repaired by proliferation of
ﬁbroblasts and vascular capillary endothelial cells
to form granulation tissue and eventually a ﬁbrous
scar. Inﬂammation occurs early after damage and
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even when only low concentrations of pathogens are
present. Therefore, proinﬂammatory cytokines such
as tumor necrosis factor (TNF)a and interleukin
(IL) 1, IL-17 and IL-18 serve to trigger and rapidly
amplify the inﬂammatory response in order to limit
spreading of the infection. Upon removal of the
causing agent the inﬂammation normally subsides.
This process is actively mediated by regulatory fac-
tors such as anti-inﬂammatory cytokines (e.g. IL-10,
IL-13) and glucocorticoids (Kubo et al., 2003).
While inﬂammation is a necessary and eﬀective
part of the normal innate immune response, in
some situations the inﬂammatory process contin-
ues even in the absence of inﬂammatory agents.
Inappropriate activation of the immune system
frequently occurs in chronic inﬂammatory dis-
eases, which are characterized by overproduction
of immune cells, tissue-destructive enzymes and
inﬂammatory cytokines. These cells and proteins
attack and destroy healthy tissue, thus causing
various diseases including rheumatoid arthritis,
asthma, inﬂammatory bowel disease, and psoriasis
(Kumar et al., 2001). As a cautionary note it should
be stated that these chronic inﬂammatory diseases
are not only caused by a single common event but
are rather caused by several, disease-speciﬁc chan-
ges. Intriguingly, chronic inﬂammatory diseases are
found frequently associated either with (I) constitu-
tively active proinﬂammatory signaling pathways
such asNF-jBor (II) dysregulated anti-inﬂammatory
signaling.
Receptor-mediated signaling pathways in the
inﬂammatory process
Early proinﬂammatory signaling is typically med-
iated by lipopolysaccharide (LPS) receptors which
directly recognize products from the invading
pathogen. Later on, further receptors including
those for IL-1 and TNFa mediate the inﬂamma-
tory response. The signaling pathways triggered by
the IL-1 and TNF receptors are extensively studied
and excellently reviewed elsewhere (Chen and
Goeddel, 2002; Dunne and O¢Neill, 2003). Brieﬂy,
stimulation of these receptors by ligand binding
induces conformational changes which attract
further proteins including adaptors lacking enzy-
matic activities and protein kinases, which phos-
phorylate their substrate proteins. These early
events funnel into several signaling pathways such
as the activation of NF-jB (see article by
M. Heinrich in this issue) and the mitogen-acti-
vated protein kinases (MAPKs) belonging to the
ERK (extracellular-signal-regulated kinase), JNK
(c-Jun N-terminal kinase) and p38 families. While
the ERK kinases are at the heart of signaling
pathways governing proliferation and diﬀerentia-
tion, JNKs and p38 kinases are important media-
tors of inﬂammation and related processes such as
cell death (Kracht and Saklatvala, 2002; Kumar et
al., 2003; Manning and Davis, 2003).
The MAPKs and their targets phosphorylate
and thus activate a variety of transcription factors
including NF-jB, AP-1, C/EBP and ETS which
contribute to the induced expression of a battery
of mediators of the inﬂammatory response
including adhesion proteins, cytokines, chemo-
kines, proteins involved in antigen presentation,
stress response genes and acute phase proteins.
MAPKs are activated by dual phosphorylation at
conserved threonine and tyrosine residues by
MAPK kinases (MAPKKs) which in turn are
substrates for MAPK kinase kinases (MAPKKKs)
(Dong et al., 2002). While the direct activators for
each MAPK are relatively well deﬁned, the highly
complex and interconnected signaling pathways
triggering activation of MAPKKs are less com-
pletely understood.
The JNK family consists of 10 JNK isoforms
that are created by alternative splicing of messen-
ger RNA transcripts derived from three genes:
JNK1, JNK2 and JNK3. Mouse knockout studies
revealed an essential contribution of JNK to
TNFa-stimulated phosphorylation of c-Jun, a
subunit of the AP-1 transcription factor complex
(Ventura et al., 2003). The JNK pathway con-
tributes to the expression of many proinﬂamma-
tory genes, including those encoding TNF, IL-2,
E-selectin and the matrix metalloproteinase
(MMP) collagenase-1 (Holzberg et al., 2003). In
addition, the JNK pathway regulates TNF pro-
duction in bacterial lipopolysaccharide-stimulated
macrophages, and in mast cells stimulated through
the FceRI receptor (Ishizuka et al., 1998).
The p38 family of MAP kinases includes
serine–threonine kinases, which are mammalian
homologues of the HOG-1 MAP kinase in
Saccharomyces cereviciae. The four known p38
isoforms share signiﬁcant amino acid homology
with each other and include p38a, p38b, p38c and
p38d (Johnson and Lapadat, 2002). p38 MAPK is
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activated by dual phosphorylation of threonine
180 and tyrosine 182 by MKK6 and probably also
MKK3. In addition, a MAPKK-independent
mechanism of p38 MAPK activation involving
TAB1 (transforming growth factor-b-activated
protein kinase 1 (TAK1)-binding protein 1) has
been described. It has been shown that its serine
kinase activity mediates phosphorylation of tran-
scription factors and regulation of downstream
gene transcription. These events mediate induced
cytokine production, platelet aggregation, regula-
tion of hepatocyte growth and contribute to
organization of the actin cytoskeleton. Further-
more, p38 exhibits regulatory eﬀects in the induc-
tion of apoptosis (Pedersen et al., 2002) and cell
diﬀerentiation (Alsayed et al., 2001) dependent on
the cell context.
Signaling pathways as frequent targets
for commonly used anti-inﬂammatory drugs
Although known and used for decades, it was dis-
covered much later that many anti-inﬂammatory
agents interfere with key signaling pathways. For
example, glucocorticoids are still frequently employed
for the treatment of chronic inﬂammations. Besides
their ability to induce/repress gene expression via
binding to the glucocorticoid receptor, a considerable
extent of their eﬃcacy may be due to their ability to
interfere with other transcription factors such asAP-1
and NF-jB (De Bosscher et al., 2003) and to inhibit
JNK signaling (Caelles et al., 1997). Another example
is cyclosporin A (CsA), which forms a complex with
cyclophilin to inhibit the phosphatase activity of cal-
cineurin. As the enzymatic activity of calcineurin is
necessary to dephosphorylate and thus activate
NF-AT, CsA prevents the activation of this tran-
scription factor and thus the induced transcription of
proinﬂammatory cytokines such as IL-2 (Matsuda
et al., 2000). Aspirin (acetylsalicylic acid) which is one
of the most widely used drugs worldwide, is a non-
steroidal anti-inﬂammatory drug (NSAIDs) that
aﬀects several pathways: First, it acetylates cycloox-
ygenases, thereby irreversibly blocking the conversion
of arachidonic acid to prostanoids. Biotransforma-
tion of aspirin yields salicylate, a compound that
possesses similar anti-inﬂammatory potency as aspi-
rin but does not display aspirin’s inhibitory eﬀect on
cyclooxygenase (Amann and Peskar, 2002). Second,
very high concentrations of aspirin or salicylate also
inhibit the activation of AP-1 or NF-jB (Kopp and
Medzhitov, 2002). The notion that commonly used
anti-inﬂammatory agents frequently target proin-
ﬂammatory signaling pathways shows that these
pathways are ideally suited as drug targets.
New drug targets: general considerations
and a few examples
During the last decade many key proteins and
signaling networks mediating the inﬂammatory
response have been discovered. It should be noted
that the importance of these key enzymes often
precludes their use as main drug targets, as
exempliﬁed by the inducible transcription factor
NF-jB. Long-lasting and systemic interference
with the NF-jB system may cause severe side
eﬀects. The importance of a functioning NF-jB
system is evident from mouse models where abla-
tion of p65 or IKKb leads to prenatal embryonic
death (Ghosh, 2004). Interference with NF-jB
activation by selective deletion of IKKb in entero-
cytes prevents the systemic inﬂammatory response,
but also results in severe apoptotic damage to the
reperfused intestinal mucosa (Chen et al., 2003).
However, NF-jB inhibitors may still be of great
therapeutical value when applied topical or for a
limited period. Natural products have proved to be
a rich source for the detection of NF-jB inhibitors
including isoprenoid compounds, sesquiterpene
lactones, triterpenoids and anti-oxidative phenolic
compounds (Bremner and Heinrich, 2002).
Although available drugs alleviate many of the
symptoms of disease, they often do not target the
underlying causative mechanisms. In that respect,
the NF-jB transcription factor and the MAPK
signaling pathways are at the apex of proinﬂam-
matory signaling. As NF-jB is activated by cyto-
kines such as IL-1 and TNFa and these cytokines
are among the numerous NF-jB target genes,
activation of this transcription factor allows the
establishment of a signal ampliﬁcation loop
(Ghosh, 2004). This process is important during
the early phase of infection and allows the rapid
ampliﬁcation of the inﬂammatory response. Dur-
ing inﬂammatory diseases, chronically hyperacti-
vated NF-jB and MAPK signaling can thus
maintain inﬂammatory signaling even in the
absence of pathogens (Tak and Firestein, 2001).
Thus, drugs designed to break this vicious circle
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are promising for a causative therapy. As TNFa
and IL-1 are crucial components driving this circle,
their inactivation by the TNF neutralizing anti-
body inﬂiximab (Remicade; Centocor) or the sol-
uble IL-1 receptor antagonist Anakinra (Kineret;
Amgen) are successfully used for the treatment of
the inﬂammatory disease rheumatoid arthritis.
Since the general inhibition of inﬂammatory sig-
naling bears the potential danger to compromise
the immune system or even general viability, new
targets must be identiﬁed that are either opera-
tional in speciﬁc tissues or alternatively only aﬀect
a subset of target genes.
A prominent example for a cell type and
pathway-speciﬁc member of the NF-jB activation
cascade is PKCh. This Ca2+-independent PKC
isotype was isolated 10 years ago as a kinase
selectively expressed in muscle cells and T lym-
phocytes (Baier et al., 1994). Biochemical and
genetic approaches revealed that PKCh is required
for the activation of mature T cells and IL-2 pro-
duction, while it is dispensable for T-cell develop-
ment. PKCh)/) T cells show impaired T cell
receptor (TCR)-induced stimulation of the tran-
scription factors AP-1 and NF-jB (Sun et al.,
2000; Pfeifhofer et al., 2003). PKCh integrates
signals from the TCR and the costimulatory CD28
receptor, which are essential for productive T-cell
activation and, most likely, for prevention of T-cell
anergy. PKCh also provides a survival signal,
which protects T cells from apoptosis. PKCh is
selectively recruited to the central supramolecular
activation complex region of the immunological
synapse in antigen-stimulated T cells (Monks
et al., 1998). This translocation is required for the
activity of PKCh and critically depends on the
adaptor protein SLP-76, phospolipase Cc (Dienz
et al., 2003) and further proteins including Vav1,
phosphatidylinositol 3-kinase, the small GTPase
Rac and reorganization of the actin cytoskeleton
(Villalba et al., 2002). The selective expression and
essential function of PKCh in T-cell activation and
survival suggest that pharmacological strategies
designed to selectively block the function of this
PKC isoform in T cells may be therapeutically
useful. PKCh inhibition could potentially abolish a
T-cell survival signal and therefore promote the
apoptosis of activated self-reactive T cells which
play a role in several autoimmune diseases such as
rheumatoid arthritis, insulin-dependent diabetes
mellitus and multiple sclerosis.
Another interesting candidate controlling only a
subset of NF-jB target genes is IKKe/IKKi. The
IKKa/b homologue IKKe (Peters et al., 2000), also
called IKKi (Shimada et al., 1999), has been
implicated in NF-jB activation. Sequence com-
parison revealed that IKKe displays 33 and 31%
amino acid identity with IKKa and IKKb, respec-
tively, within the kinase domain,. The overall sim-
ilarity throughout the entire sequence between the
kinases is 27%. Although recombinant IKKe
directly phosphorylates only serine 36 of IjBa, the
phorbol ester-activated endogenous IKKe complex
phosphorylates both critical serine residues (Peters
and Maniatis, 2001). Remarkably, this activity is
due to the presence of a distinct so-far unknown
kinase in this complex. A dominant-negative
mutant of IKKe blocks induction of NF-jB by
both PMA and activation of the T cell receptor but
has no eﬀect on the activation of NF-jB by TNFa
or IL-1. IKKe was revealed to be an essential
component of the IRF3 signaling pathway (Fitz-
gerald et al., 2003), but there is also evidence for an
involvement in the LPS response. Although the
activation of the classical IKK complex is
unchanged in IKKe)/) cells, this kinase provides a
link between signaling through the NF-jB and
CCAAA/enhancer-binding protein (C/EBP) path-
ways. This link includes an NF-jB-dependent reg-
ulation of C/EBPb and C/EBPd gene transcription
and IKKe-mediated activation of C/EBP DNA-
binding. Disruption of the NF-jB pathway results
in the blockade of the inducible up-regulation of C/
EBPb, C/EBPd, and IKKe genes. Cells lacking
IKKe fail to induce C/EBPd activity and tran-
scription of C/EBP and C/EBP-NF-jB target genes
in response to LPS. IKKe-deﬁcient mice are per-
fectly viable and studies employing IKKe)/) mouse
embryonic ﬁbroblasts reveal that this kinase is
required for the induced expression of a number of
NF-jB target genes including TNF, IL-1, IP-10,
COX-2 and RANTES (Kravchenko et al., 2003).
Other NF-jB target genes including c-jun and
many others remained completely unaﬀected, thus
revealing that IKKe only controls a distinct subset
of NF-jB-regulated genes. Given the role of IKKe
for a deﬁned array of genes and the non-essential
role of this kinase for cell viability, this kinase is an
attractive drug target.
Further interesting candidates come from
recent ﬁndings elucidating non-classical, so-called
non-canonical NF-jB activation pathways that
22
results in the release of p52/RelB (Senftleben et al.,
2001a, b; Xiao et al., 2001)as well as p50/RelB
dimers (Muller and Siebenlist, 2003). This path-
way allows NIK- and IKKa-dependent processing
of the p100 protein, which results in the liberation
of p52. The induction of p100 processing by
overexpression of NIK does not occur in the
absence of IKKa, suggesting that NIK acts
upstream from IKKa (Senftleben et al., 2001a, b).
p100 processing is independent from the classical
IKK complex and also occurs in the absence of
IKKc/NEMO or IKKb (Schiemann et al., 2001;
Senftleben et al., 2001a, b). A physiologically rel-
evant signal triggering p100 processing is lym-
photoxin b (LTb), which is important for the
organization and development of lymphoid tis-
sues. Stimulation of the LTb receptor induces
NIK- and IKKa-dependent p100 processing
(Dejardin et al., 2002) and activation of the classical
IKK complex. Accordingly, there are two subsets of
LTbR-induced genes, one activated by the canonical
pathway and another set of genes activated by the
non-canonical pathway (Dejardin et al., 2002).
Therefore, inhibition of p100 processing would not
aﬀect all NF-jB-regulated genes and inhibitors
interfering with this event are therefore of potential
interest.
In addition to the NF-jB system, also the
MAPKs JNK and p38 are control switches for
proinﬂammatory signaling, thus suggesting these
kinases as ’drugable’ structures. The JNK pathway
is required for induced expression of TNFa, IL-2,
E-selectin, and MMPs such as collagenase-1
(Holzberg et al., 2003). MMPs promote cartilage
and bone erosion in rheumatoid arthritis and gen-
eralized tissue destruction in other autoimmune
diseases. Inducible expression of MMP3, MMP9
and collagenases is regulated by activation of the
JNK pathway and AP-1 (Gum et al., 1997). Stim-
ulation of human rheumatoid synoviocytes with
TNFa or IL-1 activates the JNK pathway (Han et
al., 1999). Activated JNK can also be detected in
synovial ﬁbroblasts and chondrocytes from the
joints of osteoarthritic patients, but not from nor-
mal controls. Therefore JNK signaling has been
suggested to play a role in chondrocyte injury and
cartilage degeneration that are features of this
disease (Clancy et al., 2001; Han et al., 2001). The
dysregulation of JNK activity in multiple cell types
involved in the inﬂammatory process has drawn
attention to the development of JNK inhibitors as
immuno-modulatory agents. The JNK inhibitor
SP-600125 was reported as a selective inhibitor of
JNKs 1, 2 and 3 (IC50 = 110–150 nM), but with
much less activity against the closely related p38
MAPK (IC50 > 30 lM). This inhibitor was tested
in animal models of arthritis and asthma.
SP-600125 inhibits IL-1-induced phosphorylation
of JNK and c-Jun in synoviocytes from rheuma-
toid arthritis patients, and inhibits the production
of MMP13 which is an important mediator of
cartilage destruction (Han et al., 2001). Adminis-
tration of SP-600125 also prevents JNK activation
and collagenase expression in the joints of rats with
adjuvant arthritis. Treated rats showed a signiﬁ-
cant reduction in paw swelling and reduced dam-
age of bone and cartilage. These ﬁndings suggest
that drugs targeting the JNK signaling pathway
could be considered as a potential therapy for
rheumatoid arthritis and also other inﬂammatory
diseases.
The relevance of p38 for the inﬂammatory
process is even evident from the history of its
discovery, as it was identiﬁed as the molecular
target of the pyridinyl imidazole class of com-
pounds that were known to inhibit LPS-induced
IL-1 and TNF production in human monocytes
(Lee et al., 1994). A number of studies using the
p38 inhibitor SB203580 revealed the contribution
of p38 for induced expression of IL-1, TNFa, COX-
2, MMPs, MCP-1, IL-6, IL-8 and NO synthases
(Kracht and Saklatvala, 2002). The stimulatory
eﬀect of p38 relies on induced phosphorylation of
transcription factors such as ATF2 but also on
mRNA stabilization (Dean et al., 2003). Preclinical
studies with p38 MAP kinase inhibitors indicate a
crucial role of MAPK in inﬂammation. Speciﬁc and
selective inhibitors block the production of proin-
ﬂammatory cytokines and inﬂammatory mediators
in vitro and in vivo. In addition, p38-dependent his-
toneH3 phosphorylation marks and recruits NF-jB
to otherwise cryptic promoters, resulting in
increased expression of several inﬂammatory cyto-
kines and chemokines (Saccani et al., 2002). A large
body of evidence from preclinical studies suggests a
crucial role especially of the p38 isoform p38a in
inﬂammation.
Blocking of p38 activity has been shown to be
eﬀective in animal models of rheumatoid arthritis,
which is characterized by a debilitating joint
destruction that can be attributed to ongoing
chronic inﬂammation of the synovial lining.
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Inﬁltration of this tissue with immunocompetent
cells and proliferation of synovial ﬁbroblasts leads
to the formation of pannus tissue, which invades
and destroys the subchondral bone and articular
cartilage. As rheumatoid arthritis is characterized
by constitutively high levels of TNFa, IL-1, IL-6,
IL-7 and IL-12, interference with the production
of these cytokines by the p38 inhibitor FR167653
prevents the onset and progression of collagen-
induced arthritis in rats (Nishikawa et al., 2003).
Several novel imidazole analogues based on the
structures of the original p38 MAPK inhibitors
have now entered clinical studies and it will be
interesting to see their eﬃcacy.
Concluding remarks
Here we concentrated on featuring protein kinases
as molecular targets for anti-inﬂammatory agents.
The reason is, that most of the available preclinical
and clinical data were obtained from this class of
enzymes. On the other hand, proteins with other
enzymatic activities including phosphatases, phos-
pholipases andmany others deserve a closer look for
their suitability as drug targets. Since signal trans-
duction networks are highly connected andmutually
regulated, it might be advantageous to inhibit more
than one target. Thus, the above mentioned com-
monly used anti-inﬂammatory drugs aspirin and
glucocorticoids aﬀect more than a single molecule
and it is tempting to speculate that exactly this
attribute allows their potent eﬃcacy. The complex
nature of phytochemical preparations often allows
the simultaneous inhibition of several pathways,
making these extracts ideally suited and used for
treatment of inﬂammatory diseases. There remains
still a lot to be learned on the target proteins in
order to combine maximal eﬃcacy with minimal
side eﬀects.
Acknowledgements
We apologize to all scientists who made important
discoveries to the issue discussed here and could
not be cited due to the limitation of space. We are
grateful for the support of our work by the EU
FP6 program, Oncosuisse, Swiss National Science
Foundation and Association for International
Cancer Research.
References
Alsayed Y, Uddin S, Mahmud N, Lekmine F, Kalvakolanu
DV, Minucci S, Bokoch G & Platanias LC (2001) Activation
of Rac1 and the p38 mitogen-activated protein kinase
pathway in response to all-trans-retinoic acid. J. Biol. Chem.
276: 4012–4019.
Amann R & Peskar BA (2002) Anti-inﬂammatory eﬀects of
aspirin and sodium salicylate. Eur. J. Pharmacol. 447: 1–9.
Baier G, Baier-Bitterlich G, Meller N, Coggeshall KM, Giampa
L, Telford D, Isakov N & Altman A (1994) Expression and
biochemical characterization of human protein kinase
C-theta. Eur. J. Biochem. 225: 195–203.
Bremner P. & Heinrich M. (2002) Natural products as targeted
modulators of the NF-kappaB pathway. J. Pharm. Pharma-
col. 54: 453–472.
Caelles C, Gonzalez-Sancho JM & Munoz A (1997) Nuclear
hormone receptor antagonism with AP-1 by inhibition of the
JNK pathway. Genes Dev. 11: 3351–3364.
Chen G & Goeddel DV (2002) TNF-R1 signaling: a beautiful
pathway. Science 296: 1634–1635.
Chen LW, Egan L, Li ZW, Greten FR, Kagnoﬀ MF & Karin M
(2003) The two faces of IKK and NF-kappaB inhibition:
prevention of systemic inﬂammation but increased local
injury following intestinal ischemia-reperfusion. Nat. Med.
9: 575–581.
Clancy R, Rediske J, Koehne C, Stoyanovsky D, Amin A,
Attur M, Iyama K & Abramson SB (2001) Activation of
stress-activated protein kinase in osteoarthritic cartilage:
evidence for nitric oxide dependence. Osteoarthr. Cartilage
9: 294–299.
De Bosscher K, Vanden Berghe W & Haegeman G (2003) The
interplay between the glucocorticoid receptor and nuclear
factor-kappaB or activator protein-1: molecular mechanisms
for gene repression. Endocr. Rev. 24: 488–522.
Dean JL, Sarsﬁeld SJ, Tsounakou E & Saklatvala J (2003) p38
Mitogen-activated protein kinase stabilizes mRNAs that
contain cyclooxygenase-2 and tumor necrosis factor AU-rich
elements by inhibiting deadenylation. J. Biol. Chem. 278:
39470–39476.
Dejardin E, Droin NM,DelhaseM,Haas E, CaoY,Makris C, Li
ZW, Karin M, Ware CF & Green DR (2002) The lymphotox-
in-beta receptor induces diﬀerent patterns of gene expression
via two NF-kappaB pathways. Immunity 17: 525–535.
Dienz O, Moller A, Strecker A, Stephan N, Krammer PH,
Droge W & Schmitz ML (2003) Src homology 2 domain-
containing leukocyte phosphoprotein of 76 kDa and phos-
pholipase C gamma 1 are required for NF-kappa B activation
and lipid raft recruitment of protein kinase C theta induced by
T cell costimulation. J. Immunol. 170: 365–372.
Dong C, Davis RJ & Flavell RA (2002) MAP kinases in the
immune response. Annu. Rev. Immunol. 20: 55–72.
Dunne A & O’Neill LA (2003) The interleukin-1 receptor/Toll-
like receptor superfamily: signal transduction during inﬂam-
mation and host defense. Sci. STKE 2003: re3.
Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E,
Golenbock DT, Coyle AJ, Liao SM & Maniatis T (2003)
IKKepsilon and TBK1 are essential components of the IRF3
signaling pathway. Nat. Immunol. 4: 491–496.
Ghosh S (2004) Signaling to NF-kappaB Genes Dev. 18: 2195–
2224.
Gum R, Wang H, Lengyel E, Juarez J & Boyd D (1997)
Regulation of 92 kDa type IV collagenase expression by
24
the jun aminoterminal kinase- and the extracellular signal-
regulated kinase-dependent signaling cascades. Oncogene 14:
1481–1493.
Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM &
Firestein GS (1999) Jun N-terminal kinase in rheumatoid
arthritis. J. Pharmacol. Exp. Ther. 291: 124–130.
Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L,
Manning AM & Firestein GS (2001) c-Jun N-terminal kinase
is required for metalloproteinase expression and joint destruc-
tion in inﬂammatory arthritis. J. Clin. Invest. 108: 73–81.
Holzberg D, Knight CG, Dittrich-Breiholz O, Schneider H,
Dorrie A, Hoﬀmann E, Resch K & Kracht M (2003)
Disruption of the c-JUN–JNK complex by a cell-permeable
peptide containing the c-JUN delta domain induces apop-
tosis and aﬀects a distinct set of interleukin-1-induced
inﬂammatory genes. J. Biol. Chem. 278: 40213–40223.
Ishizuka T, Kawasome H, Terada N, Takeda K, Gerwins P,
Keller GM, Johnson GL & Gelfand EW (1998) Stem cell
factor augments Fc epsilon RI-mediated TNF-alpha pro-
duction and stimulates MAP kinases via a diﬀerent pathway
in MC/9 mast cells. J. Immunol. 161: 3624–3630.
Johnson GL & Lapadat R (2002) Mitogen-activated protein
kinase pathways mediated by ERK, JNK, and p38 protein
kinases. Science 298: 1911–1912.
Johnston B & Butcher EC (2002) Chemokines in rapid leukocyte
adhesion triggering andmigration. Semin. Immunol. 14: 83–92.
Kopp E & Medzhitov R (2002) Skin antibiotics get in the loop.
Nat. Med. 8: 1359–1360.
Kracht M & Saklatvala J (2002) Transcriptional and post-
transcriptional control of gene expression in inﬂammation.
Cytokine 20: 91–106.
Kravchenko VV, Mathison JC, Schwamborn K, Mercurio F &
Ulevitch RJ (2003) IKKi/IKKepsilon plays a key role in
integrating signals induced by pro-inﬂammatory stimuli. J.
Biol. Chem. 278: 26612–26619.
Kubo M, Hanada T & Yoshimura A (2003) Suppressors of
cytokine signaling and immunity. Nat. Immunol. 4: 1169–1176.
Kumar S, Blake SM & Emery JG (2001) Intracellular signaling
pathways as a target for the treatment of rheumatoid
arthritis. Curr. Opin. Pharmacol. 1: 307–313.
Kumar S, Boehm J & Lee JC (2003) p38 MAP kinases: key
signalling molecules as therapeutic targets for inﬂammatory
diseases. Nat. Rev. Drug Discov. 2: 717–726.
Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S,
Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter
SW & . (1994) A protein kinase involved in the regulation of
inﬂammatory cytokine biosynthesis Nature 372: 739–746.
Manning AM & Davis RJ (2003) Targeting JNK for therapeutic
beneﬁt: from junk to gold?. Nat. Rev. DrugDiscov. 2: 554–565.
Marra F (2002) Chemokines in liver inﬂammation and ﬁbrosis
Front. Biosci. 7: d1899–d1914.
Matsuda S, Shibasaki F, Takehana K, Mori H, Nishida E &
Koyasu S (2000) Two distinct action mechanisms of immu-
nophilin–ligand complexes for the blockade of T-cell acti-
vation. EMBO Rep. 1: 428–434.
Monks CR, Freiberg BA, Kupfer H, Sciaky N & Kupfer A
(1998) Three-dimensional segregation of supramolecular
activation clusters in T cells. Nature 395: 82–86.
Muller JR & Siebenlist U (2003) Lymphotoxin beta receptor
induces sequential activation of distinct NF-kappa B factors
via separate signaling pathways. J. Biol. Chem. 278: 12006–
12012.
Nishikawa M, Myoui A, Tomita T, Takahi K, Nampei A &
Yoshikawa H (2003) Prevention of the onset and progression
of collagen-induced arthritis in rats by the potent p38
mitogen-activated protein kinase inhibitor FR167653.
Arthritis Rheum. 48: 2670–2681.
Pedersen IM, Buhl AM, Klausen P, Geisler CH & Jurlander J
(2002) The chimeric anti-CD20 antibody rituximab induces
apoptosis in B-cell chronic lymphocytic leukemia cells
through a p38 mitogen activated protein-kinase-dependent
mechanism. Blood 99: 1314–1319.
Peters RT, Liao SM & Maniatis T (2000) IKKepsilon is part of
a novel PMA-inducible IkappaB kinase complex. Mol. Cell
5: 513–522.
Peters RT & Maniatis T (2001) A new family of IKK-related
kinases may function as I kappa B kinase kinases. Biochim.
Biophys. Acta 1471: M57–M62.
Pfeifhofer C, Koﬂer K, Gruber T, Tabrizi NG, Lutz C, Maly K,
Leitges M & Baier G (2003) Protein kinase C theta aﬀects
Ca2+ mobilization and NFAT cell activation in primary
mouse T cells. J. Exp. Med. 197: 1525–1535.
Saccani S, Pantano S & Natoli G (2002) p38-Dependent
marking of inﬂammatory genes for increased NF-kappa B
recruitment. Nat. Immunol. 3: 69–75.
Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-
Morskaya S, Dobles M, Frew E & Scott ML (2001) An
essential role for BAFF in the normal development of B
cells through a BCMA-independent pathway. Science 293:
2111–2114.
Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G,
Chen Y, Hu Y, Fong A, Sun SC & Karin M (2001a)
Activation by IKKalpha of a second, evolutionary conserved,
NF-kappaB signaling pathway. Science 293: 1495–1499.
Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G,
Chen Y, Hu Y, Fong A, Sun SC & Karin M (2001b)
Activation by IKKalpha of a second, evolutionary conserved,
NF-kappaB signaling pathway. Science 293: 1495–1499.
Shimada T, Kawai T, Takeda K, Matsumoto M, Inoue J,
Tatsumi Y, Kanamaru A & Akira S (1999) IKK-i, a novel
lipopolysaccharide-inducible kinase that is related to Ikap-
paB kinases. Int. Immunol. 11: 1357–1362.
Sun Z, Arendt CW, Ellmeier W, Schaeﬀer EM, Sunshine MJ,
Gandhi L, Annes J, Petrzilka D, Kupfer A, Schwartzberg PL
& Littman DR (2000) PKC-theta is required for TCR-
induced NF-kappaB activation in mature but not immature
T lymphocytes. Nature 404: 402–407.
Tak PP & Firestein GS (2001) NF-kappaB: a key role in
inﬂammatory diseases. J. Clin. Invest. 107: 7–11.
Ventura JJ, Kennedy NJ, Lamb JA, Flavell RA & Davis RJ
(2003) c-Jun NH(2)-terminal kinase is essential for the
regulation of AP-1 by tumor necrosis factor. Mol. Cell. Biol.
23: 2871–2882.
Villalba M, Bi K, Hu J, Altman Y, Bushway P, Reits E, Neefjes
J, Baier G, Abraham RT & Altman A (2002) Translocation
of PKC[theta] in T cells is mediated by a nonconventional,
PI3-K- and Vav-dependent pathway, but does not absolutely
require phospholipase C. J. Cell Biol. 157: 253–263.
Winrow VR, Winyard PG, Morris CJ & Blake DR (1993) Free
radicals in inﬂammation: second messengers and mediators
of tissue destruction. Br. Med. Bull. 49: 506–522.
Xiao G, Harhaj EW & Sun SC (2001) NF-kappaB-inducing
kinase regulates the processing of NF-kappaB2 p100. Mol.
Cell 7: 401–409.
25
